(Q44371875)

English

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours

scientific article published in April 2003

Statements

An EORTC-ECSG phase I study of LU 79553 administered every 21 or 42 days in patients with solid tumours (English)

Identifiers

 
edit
    edit
      edit
        edit
          edit
            edit
              edit
                edit
                  edit